Nutra Pharma Announces Collaborative Agreement with Centers for Disease Control and Prevention (CDC)
2008-08-06 08:00:00
Nutra Pharma Announces Collaborative Agreement with Centers for Disease Control and Prevention (CDC)
BOCA RATON, Fla.–(EMWNews)–Nutra Pharma Corp. (OTCBB:NPHC), a biotechnology company that is
developing drugs for HIV and Multiple Sclerosis, has announced today
that its wholly-owned drug discovery subsidiary, ReceptoPharm, Inc., has
renewed its collaborative agreement with the Centers for Disease Control
and Prevention (CDC) to study RPI-78M and RPI-MN as a possible therapy
for Rabies. RPI-78M is ReceptoPharm’s leading
drug candidate for the treatment of autoimmune and neurological
disorders and RPI-MN is ReceptoPharm’s leading
antiviral drug candidate.
“This collaboration with the CDC allows us to
analyze various formulas for both RPI-78M and RPI-MN as possible
treatments for Rabies,” explained Paul Reid,
CEO of ReceptoPharm. “Our goal with this study
is to better understand the mechanism of action of our leading drug
candidates and to determine their potential for treating advanced Rabies
infections,” he concluded.
Rabies is a virus that infects the central nervous system and is
characterized by inflammation in the brain (encephalitis). The virus is
most often transmitted through the bite of a rabid animal, which
commonly include raccoons, foxes and bats. Currently there is a
post-exposure vaccination available to people exposed to rabies. If left
untreated, Rabies is fatal. According to the World Health Organization,
as many as 55,000 people worldwide die annually from Rabies infections.
About Nutra Pharma Corp.
Nutra Pharma Corp. is a biopharmaceutical company specializing in the
acquisition, licensing and commercialization of pharmaceutical products
and technologies for the management of neurological disorders, cancer,
autoimmune and infectious diseases. Nutra Pharma Corp. through its
subsidiaries carries out basic drug discovery research and clinical
development and also seeks strategic licensing partnerships to reduce
the risks associated with the drug development process. The Company’s
subsidiary, ReceptoPharm, Inc., is developing these technologies for the
production of drugs for HIV and Multiple Sclerosis (“MS”). The Company’s
subsidiary, Designer Diagnostics, is engaged in the research and
development of diagnostic test kits designed to be used for the rapid
identification of infectious diseases such as Tuberculosis (TB) and
Mycobacterium avium-intracellulare (MAI). Nutra Pharma continues to
identify and acquire intellectual property and companies in the
biotechnology arena.
SEC Disclaimer
This press release contains forward-looking statements. The words or
phrases “would be,” “will allow,” “intends to,” “will likely result,”
“are expected to,” “will continue,” “is anticipated,” “estimate,”
“project,” or similar expressions are intended to identify
“forward-looking statements.” Actual results could differ materially
from those projected in Nutra Pharma’s (“the Company”) business plan.
The Company’s business is subject to various risks, which are discussed
in the Company’s filings with the Securities and Exchange Commission
(“SEC”). The collaborative agreement with the CDC
should not be construed as an indication in any way whatsoever of the
value of the Company or its common stock. The Company’s filings
may be accessed at the SEC’s Edgar system at www.sec.gov.
Statements made herein are as of the date of this press release and
should not be relied upon as of any subsequent date. The Company
cautions readers not to place reliance on such statements. Unless
otherwise required by applicable law, we do not undertake, and we
specifically disclaim any obligation, to update any forward-looking
statements to reflect occurrences, developments, unanticipated events or
circumstances after the date of such statement.
|
Nutra Pharma Corp., Boca Raton Isserman, 877-895-5647 |
|
Major Newsire & Press Release Distribution with Basic Starting at only $19 and Complete OTCBB / Financial Distribution only $89
Get Unlimited Organic Website Traffic to your Website
TheNFG.com now offers Organic Lead Generation & Traffic Solutions
